Significant hyperbilirubinemia among well neonates due for discharge at Kawempe-Mulago Hospital, prevalence, factors associated, and accuracy of transcutaneous bilirubinometry for screening

Carolyn Nassuna1, Abdallah Yaser1, Charles Karamagi1, Jamir Mugalu1,2

1. Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda.
2. Mulago National Referral hospital, Kampala, Uganda.

Abstract

Background: Neonates in low resource settings with a lack of pre-discharge screening and early intervention are at risk for complications associated with significant hyperbilirubinemia (SHB).

Objectives: To determine the prevalence, factors associated and performance of transcutaneous bilirubin (TCB) in identifying well neonates with SHB.

Methods: Over a one month period 235 well neonates 24 to 72 hours of age due for discharge at Kamempe-Mulago Hospital were enrolled in this study. Visual inspection using Kramer rule, transcutaneous bilirubin over the sternum using Draeger JM103 bilirubinometer, and serum bilirubin were determined. Neonates with SHB (total serum bilirubin warranting treatment) were referred for treatment. Relevant data were analyzed. A P-value of <0.05 was considered significant at 95% confidence interval.

Results: Thirty two (13.6%) of the neonates had SHB and three (1.3%) had levels above exchange transfusion threshold. Significant hyperbilirubinemia was independently associated with CRP ≥ 10mg/l (AOR 3.96, CI 1.23-12.73, p 0.021), ABO discordance (AOR 3.67, CI 1.28-10.49, p 0.015), jaundice in a previous sibling (AOR 3.565, CI 1.10-11.51, p 0.034) and time of first feed > 1 hour (AOR 2.74, CI 1.10-6.90, p 0.007). The sensitivity, specificity, positive and negative predictive values of TCB were 96.5%, 84.6%, 47.5% and 99.4% respectively compared to 31.2%, 98.5%, 76.9% and 90% respectively for visual assessment (Kramer grading).

Conclusions: A significant number of well neonates have SHB. Transcutaneous bilirubinometry is a suitable screening tool in this setting. Early initiation of feeding should be promoted. The cause for high CRP among well neonates with SHB needs to be studied further.

Keywords: Significant Hyperbilirubinemia, transcutaneous bilirubinometer.

DOI: https://dx.doi.org/10.4314/ahs.v22i2.61

Cite as: Nassuna C, Yaser A, Karamagi C, Mugalu J. Significant hyperbilirubinemia among well neonates due for discharge at Kawempe-Mulago Hospital, prevalence, factors associated, and accuracy of transcutaneous bilirubinometry for screening. Afri Health Sci. 2022;22(2): 526-534. https://dx.doi.org/10.4314/ahs.v22i2.61

Background

Jaundice affects 60% to 80% of all neonates the majority of whom no intervention is needed, but approximately 5-15% will develop significant jaundice/hyperbilirubinemia (Serum bilirubin >95th percentile on Bhutani hourly specific bilirubin nomogram) to warrant close monitoring and/or treatment1-4. Underlying conditions like prematurity, sepsis, blood group incompatibility, G6PD deficiency, inadequate feeding among others may cause a rapid rise of bilirubin leading to severe neonatal jaundice (SNJ) (Significant jaundice with acute neurologic changes or needing exchange blood transfusion) necessitating hospitalization5,6.

Severe neonatal jaundice is among the leading causes for hospitalization in the first month of life6,8. Neonates with SNJ may progress to brain dysfunction (acute bilirubin encephalopathy (ABE)) and death while those who survive following ABE are at risk for disabilities9,10. In the developed countries systematic risk assessment for SNJ, bilirubin level estimation and timely intervention have considerably reduced SNJ, need for exchange transfusions and SNJ associated disabilities11,12.
Globally SNJ affects 481,000 term/near term neonates annually; of these 114,000 die and 63,000 survive with disability.13 The majority of such neonates are in Low and Middle-income countries (LMICS) due to health system bottlenecks that hinder screening and early treatment.6,7,13,14 Whereas the WHO recommends 24-hour hospital stay after uncomplicated delivery, pre-discharge jaundice assessment, 72 hours and day 7 reviews; implementation of these recommendations has been challenging in LMICS for various reasons.

At Kawempe-Mulago hospital (KMH) with its high patient volume; well neonates are discharged by 6-12 hours of age and are not screened for jaundice. In view of the consequences associated with SHB; we conducted this study at KMH to determine the prevalence of SHB and associated factors among well neonates so as to define the magnitude of the problem and advice policy. This high patient volume and short hospital stay renders serum bilirubin screening not feasible so we assessed the performance of transcutaneous bilirubinometry and visual inspection as alternatives screening methods.

Methods
Study Setting
This study was conducted at the postnatal ward of the Kawempe-Mulago National Referral Hospital (KMH). Kawempe-Mulago Hospital is Uganda’s National Referral Hospital and the training hospital for Makerere College of Health Sciences it records 31,000 deliveries annually.

After delivery well neonates are kept by the mother’s side in the postnatal ward where the mother-baby pair is observed for 6-12 hours following normal vaginal delivery and 72 hours following cesarean delivery. In the postnatal ward exclusive breastfeeding is encouraged and health education given to the mothers. The neonates are assessed by midwives and initial vaccines (BCG and Oral Polio) are administered. Unwell neonates are reviewed by a doctor and transferred to the Special Care Baby Unit (SCBU) for further care if needed. Well neonates continue rooming-in with their mother until discharge. At discharge parents are advised to take the baby to a nearby health facility after one week for review. The postnatal ward does not have a structured protocol for review of the neonate.

Study Design
This was a cross-sectional study.

Study Population
Well neonates 24 to 72 hours of age due for discharge and whose parents have consented to participate in the study. A well neonate was one reported by the midwife to have no concerns and is awaiting discharge.

Sample size
Because we recruited neonates ≥ 24 hours of age, the majority of our study participants were born by cesarean section since most vaginally delivered babies would have been discharged by then. With approximately 31,000 annual deliveries and 25% cesarean section rate, the available population to us over 1 month period was approximately 646. Estimated sample size from the available population considering a prevalence for significant hyperbilirubinemia in Kenya of 34%(8) using Open-Epi for population survey at 95% CI, was 227 babies. Assuming a 3.5% for the incompleteness of data our final sample size was 235.

Study Procedure
Parents or primary caregivers of the neonates who meet study criteria were given information about the study and informed consent was obtained by the principal investigator/research assistants. History was taken and study neonates examined by the principal investigator or research assistant.

Gestational age was determined using mother’s records where available and the New Ballard Score conducted by the trained research assistant. Anthropometries were taken. Data capturing sheet was used to enter the relevant information.

Risk factors for SHB considered in the datasheet included blood group, mode of delivery, gestational age, the risk for sepsis (rupture of membrane >18 hours, maternal intrapartum fever, and offensive liquor), history of jaundice in a previous child, time of initiating feeds, bruising/cephalohematoma and weight loss (≥ 75th percentile in the application tool for monitoring weight loss in newborn).18

Study neonates were assessed for jaundice by visual inspection and graded as per the Kramer rule; we set Kramer grade 0,1,2,3,4 and 5 to correspond to bilirubin levels <80μmol/l, 80-100μmol/l, 101-150μmol/l, 151-200μmol/l, 201-250μmol/l and > 250μmol/l respectively. Visual assessment was done by a trained research assistant just prior to blood sampling. After the research assistant determined the Kramer score the principal investigator repeated the score. If there was disagreement between the two scores, the Kramer-
core obtained by the principal investigator was taken as final. Transcutaneous Bilirubin (TCB) measurement was done by the principal investigator using a calibrated Draeger JM103 transcutaneous bilirubinometer over the sternum. We ensured the interval between transcutaneous bilirubinometry and blood sampling was not >30 minutes.

For all study neonates 1mls of blood was collected by venipuncture for total serum bilirubin, blood grouping and C-reactive protein. The blood collection sites were cleaned with 70% alcohol and allowed to air dry. Blood samples were dispensed into EDTA-free containers, placed in biohazard bags then placed in a transport box to minimize direct light exposure. The samples were transported within one hour to Mulago chemistry laboratory. Total serum bilirubin was determined by the diazo colorimetric method using COBAS 6000 bilirubin analyzed. The laboratory calibrates the COBAS 6000 machine on a daily basis to ensure the validity of results.

Mother’s documented blood group was ascertained and for those with no blood group documented; blood grouping was done. Neonate found to have SHB i.e any level 20µmol/l within treatment threshold or greater on the age specific bilirubin nomogram (Using the neonatal academic hospitals’ consensus guidelines for South African hospitals and primary care facilities)²⁰, elevated CRP >10mg/dl and those with fever were referred to the SCBU for further management.

Data management and analysis
Information captured in the datasheet was checked by the principal investigator for completeness and accuracy. Data were entered into the computer using Epi-data version 3.0 and thereafter exported into STATA version 14.0 for analysis with the help of a statistician. The baseline characteristics of study participants were summarized in a table. The prevalence of SHB was computed as a ratio of neonates with total serum bilirubin warranting treatment to the total number of study neonates. Univariate analysis was conducted for continuous variables. Multivariate analysis was conducted for factors associated with SHB was determined in a stepwise manner. A P-value of < 0.05 was considered significant and confidence interval of 95% was used. Through a 2x2 table; the performance of transcutaneous bilirubinometer and visual assessment were determine. The sensitivity, specificity, positive and negative predictive values were computed. Results were summarized in tables.

Results
Between 29st March 2017 and 3rd May 2017 a total of 235 neonates were enrolled. The average age at enrollment was 49 (±14.4) hours. The median birth weight was 3.15kg (range 1.9-4.6kg). Sixty seven neonates delivered vaginally were enrolled; these neonates were not yet discharged because of maternal health concerns.
Table 1: Baseline characteristics and factors associated with significant hyperbilirubinemia

| VARIABLES                        | Significant hyperbilirubinemia | OR (95%CI) | p-value |
|----------------------------------|-------------------------------|------------|---------|
|                                  | No (203)                      | Yes (32)   |         |
| Sex                              |                               |            |         |
| Male                             | 108(53.2)                     | 18(56.2)   | 1.13(0.53-2.39) | 0.748 |
| Female                           | 95(46.8)                      | 14(43.8)   |         |
| Gestational age                  |                               |            |         |
| ≤37+6                            | 28(13.8)                      | 7(21.9)    | 1.85(0.73-4.67) | 0.193 |
| ≥38                              | 175(86.2)                     | 25(78.1)   |         |
| Birth weight                     |                               |            |         |
| <2.5kg                           | 14(7.0)                       | 3(9.4)     | 1.39(0.37-5.15) | 0.616 |
| 2.5-3.9kg                        | 179(88.1)                     | 25(78.1)   |         |
| ≥4kg                             | 10(4.9)                       | 4(12.5)    | 2.75(0.80-9.39) | 0.105 |
| Jaundice in previous baby        |                               |            |         |
| Yes                              | 15(7.4)                       | 7(21.9)    | 3.50(1.30-9.44) | 0.013 |
| No                               | 188(92.6)                     | 25(78.1)   |         |
| Time of first feed               |                               |            |         |
| ≤1 hour                          | 124(61.1)                     | 14(43.8)   | 2.25(1.05-4.79) | 0.036 |
| >1 hour                          | 79(38.9)                      | 18(56.2)   |         |
| Excessive weight loss*           |                               |            |         |
| Yes                              | 35(19.1)                      | 3(11.1)    | 0.5(0.14-1.79) | 0.294 |
| No                               | 148(80.9)                     | 24(88.9)   |         |
| Rupture of membrane (ROM)        |                               |            |         |
| ≥18hrs                           | 11(5.4)                       | 1(3.1)     | 0.56(0.07-4.51) | 0.589 |
| <18hrs                           | 192(94.6)                     | 31(96.9)   |         |
| Mother-infant ABO discordanceª   |                               |            |         |
| Yes                              | 21(12.4)                      | 9(31.0)    | 3.17(1.27-7.87) | 0.013 |
| No                               | 148(87.6)                     | 20(69.0)   |         |
| Mother-infant Rh discordanceª    |                               |            |         |
| Yes                              | 165(97.6)                     | 27(93.1)   | 3.05(0.53-17.5) | 0.22  |
| No                               | 4(2.4)                        | 2(6.9)     |         |
| C-reactive proteinª              |                               |            |         |
| <10                              | 151(91.5)                     | 22(73.3)   | 3.92(1.47-10.42) | <0.006 |
| ≥10                              | 14(8.5)                       | 8(26.7)    |         |
| Mode of delivery                 |                               |            |         |
| Caesarean section                | 141(69.5)                     | 27(84.4)   | 2.14(0.78-5.85) | 0.136 |
| Vaginal delivery                 | 62(30.5)                      | 5(15.6)    |         |
| HIV exposure                     |                               |            |         |
| Yes                              | 23 (11.3)                     | 1(3.1)     | 0.18(0.03-1.93) | 0.252 |
| No                               | 180(88.7)                     | 31(96.9)   |         |

*25 neonates did not have birth weights  *Missing lab results were excluded

The majority were exclusively breast fed (96%). Of the vaginal delivered 55/67 (82.1%) breast fed within the first hour compared to 83/168 (49.4%) by cesarean section. Thirty eight neonates had excessive weight loss, of these 19/138 fed < 1 hour and 19/97 fed ≥ 1 hour after birth. Thirty two (13.6%) of the neonates had SHB (Table 1); 15 had TSB above phototherapy threshold, 14 had ≤ 20µmol/l below phototherapy threshold and 3 above exchange transfusion threshold. The mean TSB among neonates with SHB was 240µg/l (range132-481µmol/l). Twenty two neonates had elevated CRP; 9 had fever but 13 were well with no risk for sepsis. Visible jaundice was apparent in 43(18.3%) neonates graded as Kramer grade 3, 2 and 1 in 6, 7 and 30 neonates respectively.

From the univariate analysis factors 4 factors with p<0.2 and scientific rational were included in the multivariate analysis to determine factors independently associated with SHB see Table 2.
Table 2: Factors independently associated with significant hyperbilirubinemia

| Variables                                | Adjusted Odds Ratio | 95% Conf. Interval   | P-value |
|------------------------------------------|---------------------|----------------------|---------|
| Jaundice in previous baby                |                     |                      |         |
| No                                       | 1                   |                      |         |
| Yes                                      | 3.565               | (1.10-11.51)         | 0.034   |
| Time of First feed <1hr                  |                     |                      |         |
| No                                       | 2.74                | (1.10-6.90)          | 0.007   |
| Yes                                      | 1                   |                      |         |
| C-reactive protein <10                   | 1                   |                      |         |
| ≥10                                      | 3.962               | (1.23-12.73)         | 0.021   |
| ABO discordance                          |                     |                      |         |
| No                                       | 1                   |                      |         |
| Yes                                      | 3.670               | (1.28-10.49)         | 0.015   |

To elaborate on how well visual assessment identified the level of TSB we categories our neonates in to 6 groups based on TSB range; along with this we described how they had been categories by visual assessment see table 3. Only 110 Kramer scores obtained by principal investigator and 104 by research assistant correctly predicted TSB level. Visual assessment correctly identified majority of neonates with TSB <100µmol/l but with increasing TSB level visual assessment became less accurate.

To determine the performance of TCB and visual assessment as screening modalities with TSB as the gold standard we categories neonates who were correctly assigned treatment as compared to the TSB. TCB correctly identified the majority of neonates who needed phototherapy 28/32 (87.5%) while visual assessment correctly identified the majority of those who did not need phototherapy 200/203(98.5%).

Table 3: Total serum bilirubin and Kramer grading of study neonates

| TSB level (µmol/l) | Number of neonates and Kramer grading (corresponding serum bilirubin in µmol/l) | Number of neonates | Number of neonates |
|--------------------|---------------------------------------------------------------------------------|-------------------|-------------------|
|                    | 0 (<80)                           | 1 (80-100)       | 2 (101-150)      | 3 (151-200)     | 4 (201-250)    | 5 (>250)    |
| <80                | 83                                | 82                | 0                 | 1               |               |             |
| 80-100             | 27                                | 0                 | 27                |                |               |             |
| 101-150            | 65                                | 53                | 12                |                |               |             |
| 151-200            | 39                                | 26                | 9                 | 3               | 1             |             |
| 201-250            | 11                                | 3                 | 5                 | 2               | 1             |             |
| >250               | 10                                | 1                 | 4                 | 2               | 3             |             |

Table 4: Sensitivity, specificity and accuracy of TCB and Kramer grading

| Needed Phototherapy | TCB* Correctly assigned | TCB* Wrongly assigned | Kramer grading Correctly assigned | Kramer grading Wrongly assigned |
|---------------------|-------------------------|-----------------------|----------------------------------|--------------------------------|
| Yes                 | 32                      | 28                    | 31                               | 10                             |
| No                  | 203                     | 171                   | 1                                | 200                            |

Performance of screening methods

|                     | TSB | TCB | Kramer grading |
|---------------------|-----|-----|----------------|
| Sensitivity %       | 100 | 96.5| 31.2           |
| Specificity%        | 100 | 84.6| 98.5           |
| PPV%                | 100 | 47.5| 76.9           |
| NPV%                | 100 | 99.4| 90.0           |

*TCB was obtained on 235 study neonates but only 231 used in the analysis because 4 TCB's were performed
>30 minutes after blood samples were drawn.
Discussion

The prevalence of significant hyperbilirubinemia within the first 72 hours of life in our study was 13.6% with three neonates (1.3%) having serum bilirubin levels above exchange transfusion threshold. This prevalence seems lower than that observed in the Kenyan study from which we derived our sample size although this could be because they included neonates up to 28 days of life.

A study conducted in Egypt looking at predictors of significant jaundice among well neonates without risk factors in the first 5 days found a prevalence of 16% (3), which was slightly higher than ours but we attribute this to their recruiting neonates beyond 72 hours of age.

From our literature search we noted very scanty literature on hyperbilirubinemia among well neonates in the first 72 hours of life from LMICs. When we compare our prevalence to those observed in other studies, from which SHB in the first 72 hours could be derived, our prevalence was higher; it should be noted that of the 32 neonates with SHB in this study 14 had TSB below phototherapy threshold but by the South African guidelines which we used these neonates are categorized as having SHB.

Three (3) of the neonates in this study had bilirubin levels at exchange transfusion threshold with serum bilirubin levels of 332.3, 420 and 481.4µmol/l before 60 hours of life. These are examples of neonates in LMICs likely to be discharged home only to suffer consequences of SHB due to lack of risk assessment and predischarge screening.

Thirty blood group O mothers gave birth to neonates with a different blood 30/198 (15.1%) this finding is similar to that observed in Nigeria. Nine of the neonates born to these 30 mothers developed SHB. ABO discordance was independently associated with SHB (AOR 3.6, CI 1.28-10.49 p 0.015) (Table 2). Of the 7 neonates with history of jaundice in previous sibling 5 had ABO/Rh discordance while the other two no reason could be identified. Other familial causes of neonatal jaundice including G6PD deficiency, hemoglobinopathies and enzymopathies could explain this occurrence. History of jaundice in previous infant is a known risk factor for jaundice in subsequent infant and should always be asked.

The neonates in this study whose first feed were ≥1 hour after birth were more likely to develop SHB (AOR 2.74, CI 1.1-6.9 p 0.007) (Table 2). This finding is similar to that observed in the Zimbabwean study that looked at early initiation of breastfeeding on jaundice. Inadequate enteral feeds favors increased entero-hepatic circulation and jaundice. The importance of early initiation of breastfeeding cannot be over emphasized. Of the 235 study neonates enrolled 210 had both birth weight and weight at enrollment verified. Thirty eight 38/210 (18.1%) had excessive weight loss. Only 3/38 of the neonates with excessive weight loss had SHB (Table 1), this finding is contrary to findings from other-
er studies that have demonstrated high weight loss being associated with SHB. The reason for our finding might lie in the fact that the number of neonates with excessive weight loss was small and our screening was done before the peak time which tends to occur between 3 and 5 days of life.

The majority of the neonates with SHB (37.5%) the cause could not be ascertained. Whereas identification of the cause for significant hyperbilirubinemia is important in deciding the course of management and family counseling for future pregnancies, the cause may not be established in as high as 50% of cases. Uganda has a high prevalence of G6PD deficiency and other hemoglobinopathies, it would be important to ascertain how much these contribute to SHB.

Transcutaneous bilirubin identified the majority of neonates with SHB compared to visual inspection. This is in line with findings from other studies that found TCB to yield results that highly correlate with serum levels even among black African infants. Transcutaneous bilirubinometry is steadily being accepted as modality for screening term neonates predischarge and can be easily adopted in our setting.

Visual assessment for jaundice is a very well described process but its accuracy is very subjective that even specialists using it wrongly predict bilirubin levels. From our study the majority of neonates with jaundice could be identified by visual inspection but grading of the jaundice was poor. Both the trained research assistant and the principal investigator through visual inspection tended to underestimate serum bilirubin level with Kramer scores by the research assistant being lower than that obtained by the principal investigator. We observed with increasing serum bilirubin visual inspection poorly predicted serum bilirubin level. The Kramer grading was found to have a very low sensitivity and we therefore do not recommend it for screening.

Conclusion
Significant hyperbilirubinemia is prevalent among well neonates due for discharge. Transcutaneous bilirubinometry identifies majority of neonates with SHB. Delayed initiation of feeding is a risk factor for SHB. Observed phenomenon of well neonates with SHB and elevated CRP without identifiable reason needs to be explored.

Study Limitation
The majority of the neonates were delivered by caesarian section hence our findings might not be very representative of neonates delivered vaginally. We could not do coombs test, blood cultures, screening for congenital infections like toxoplasmosis, rubella, cytomegalovirus, herpes, urinalysis, film comment and G6PD assay to ascertain other causes of significant hyperbilirubinemia. Total serum bilirubin tends to peak at 3 to 5 days of life so some of our study infants might have developed significant jaundice after the study period.

What is already known? Screening neonates for jaundice is necessary in identifying those at risk for significant hyperbilirubinemia. Transcutaneous bilirubinometry is a good screening tool for hyperbilirubinemia.

What this study adds? In the first 72 hours of life 1 in every 10 neonates have significant hyperbilirubinemia and 1 in every 100 may have bilirubin level approaching exchange transfusion threshold. Delayed initiation of feeds increases risk for hyperbilirubinemia.

List of abbreviations
Rh: Rhesus
ABO: Blood groups A, B and O
CRP: C-reactive protein
LMICs: Low and Middle Income Countries
SCBU: Special Care Baby Unit
SHR: Significant Hyperbilirubinemia
TCB: Transcutaneous Bilirubin
TSB: Total Serum Bilirubin
WHO: World Health Organization

Declaration
Ethics approval and consent to participate
Ethical approval to conduct this study was obtained from the Makerere Colleague of Health Sciences Institution review board. Written informed consent was obtained from the parents of study participants.

Consent to publish
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interest
None of the authors have any conflict of interest to declare.
Funding
This study received no external funding.

Authors’ contribution
N.C collected and entered the data; she along with Y.A reviewed literature and did the write up. K.C and M.J reviewed the literature, methodology and write up. All authors approved the final version of this work.

Acknowledgement
The maternity unit and staff for their support during the study period. The mothers of our study participants for accepting to participate in the study.

References
1. Rennie J, Burman-Roy S, Murphy MS. Neonatal jaundice: summary of NICE guidance. BMJ 2010 10.1136/bmj.c2409;340(4):c2409.
2. Bhutani VK, Vilms RJ, Hamerman-Johnson L. Universal bilirubin screening for severe neonatal hyperbilirubinemia. J Perinatol 2010 Oct;30 Suppl:S6-15.
3. Khairy MA, Abuelhamd WA, Elhawary IM, Mahmoud Nabayel AS. Early predictors of neonatal hyperbilirubinemia in full term newborn. Pediatr Neonatal. 2019 Jun;60(3):285-290.
4. Nishanth R, Peter PK, Lalitha K, Manikandan M. Significant Hyperbilirubinemia in Near term and Term Newborns: a case–control study. JCN Oct-Dec2017;6(4).
5. Olusanya BO, Osibanjo FB, Slusher TM. Risk factors for severe neonatal hyperbilirubinemia in low and middle-income countries: a systematic review and meta-analysis. PLoS One 2015 Feb 12;10(2):e0117229.
6. Olusanya BO, Kaplan M, Hansen TWR. Neonatal hyperbilirubinemia: a global perspective. Lancet Child Adolesc Health 2018 Aug;2(8):610-620.
7. Slusher TM, Zamora TG, Appiah D, Stanke JU, Strand MA, Lee BW, et al. Burden of severe neonatal jaundice: a systematic review and meta-analysis. BMJ Paediatr Open 2017 Nov 25;1(1):e000105.
8. Greco C, Arnolda G, Boo NY, Iskander IF, Okolo AA, Rohisswatmo R, et al. Neonatal Jaundice in Low- and Middle-Income Countries: Lessons and Future Directions from the 2015 Don Ostrow Trieste Yellow Retreat. Neonatology 2016;110(3):172-180.
9. Mwaniki MK, Atieno M, Lawn JE, Newton CR. Long-term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. Lancet 2012 Feb 4;379(9814):445-452.
10. Shapiro SM. Bilirubin toxicity in the developing nervous system. Pediatr Neurol 2003 Nov;29(5):410-421.
11. Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C, Tilford JM. Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988-2005. Pediatrics 2009 Feb;123(2):524-532.
12. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics 2009 Oct;124(4):1031-1039.
13. Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013 Dec;74 Suppl 1:86-100.
14. Olusanya BO, Teeple S, Kassebaum NJ. The Contribution of Neonatal Jaundice to Global Child Mortality: Findings From the GBD 2016 Study. Pediatrics 2018 Feb;141(2):e20171471.
15. WHO. WHO Recommendations on Postnatal Care of the Mother and Newborn. Geneva: WHO October 2013.
16. Nakimuli A, Nakubulwa S, Kakaire O, Osinde MO, Mbalinda SN, Nabirye RC, et al. Incidence and determinants of neonatal morbidity after elective caesarean section at the national referral hospital in Kampala, Uganda. BMC Res Notes 2015 Oct 30;8:624.
17. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, et al. New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991 Sep;119(3):417-423.
18. AAP News. Tool monitors weight loss in breast fed babies. American Academy of Pediatrics 2015;36(2):27.
19. Kramer LI. Advancement of dermal icterus in the jaundiced newborn. Am J Dis Child 1969;118:454–8. PubMed
20. Horn AR, Kirsten GF, Kroon SM, Henning PA, Möller G, Pieper C, et al. Phototherapy and exchange transfusion for neonatal hyperbilirubinemia: neonatal academic hospitals' consensus guidelines for South African hospitals and primary care facilities. S Afr Med J 2006 Sep;96(9):819-24. PubMed
21. Tikmani SS, Warraich HJ, Abbasi F, et al. Incidence of neonatal hyperbilirubinemia: a population-based prospective study in Pakistan. Trop Med Int Health 2010;15:502–7. PubMed
22. Maisels MJ, Gifford K. Normal serum bilirubin levels in the newborn and the effect of breast-feeding. Pediatrics 1986 Nov;78(5):837-843. PubMed
23. Bhutani VK, Stark AR, Lazzeroni LC, Poland R, Gourley GR, Kazmierczak S, et al. Predischarge Screening for Severe Neonatal Hyperbilirubinemia Identifies Infants Who Need Phototherapy. The Journal of Pediatrics 2013 March 2013;162(3):477 PubMed -482.e1.
24. Akanmu AS, Oyedeji OA, Adeyemo TA, Og- 533 African Health Sciences, Vol 22 Issue 2, June, 2022
benna AA. Estimating the Risk of ABO Hemolytic Disease of the Newborn in Lagos. J Blood Transfus 2015;2015:560738.
25. Hofer N, Zacharias E, Muller W, Resch B. An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks. Neonatology 2012;102(1):25-36.
26. Mjelle AB, Gudte HJT, Reigstad H, Bjorke-Monsen AL, Markestad T. Serum concentrations of C-reactive protein in healthy term-born Norwegian infants 48-72 hours after birth. Acta Paediatr 2019 May;108(5):849-854.
27. Perrone S, Lotti F, Longini M, Rossetti A, Bindi I, Bazzini F, et al. C reactive protein in healthy term newborns during the first 48 hours of life. Arch Dis Child Fetal Neonatal Ed 2018 Mar;103(2):163-166.
28. The Alliance for Maternal and Newborn Health Improvement (AMANHI) mortality study group. Population-based rates, timing, and causes of maternal deaths, stillbirths, and neonatal deaths in south Asia and sub-Saharan Africa: a multi-country prospective cohort study. Lancet Glob Health. 2018;6:e1297-308.
29. Gladys M, Mathilda Z, Zvanyadza G, Babill St. Early breast feeding initiation and incidence of severe jaundice in Chipinge district Zimbabwe. Int J Contemp Pediatr. 2017;4(6):1922-1926.
30. Gourley GR. Breast-feeding, neonatal jaundice and kernicterus. Semin Neonatol 2002 Apr;7(2):135-141.
31. Narang A, Gathwala G, Kumar P. Neonatal jaundice: an analysis of 551 cases. Indian Pediatr 1997 May;34(5):429-432.
32. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ 2006 Sep 12;175(6):587-590.
33. Roh ME, Oyet C, Orirkiza P, Wade M, Mwang-Aumpaire J, Boum Y, et al. Screening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda. Am J Trop Med Hyg 2016 Nov 2;95(5):1094-1099.
34. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation Pediatrics. 2004;114:297-316. PubMed
35. Slusher TM, Angyo IA, Bode-Thomas F, Akor F, Pam SD, Adetunji AA, et al. Transcutaneous bilirubin measurements and serum total bilirubin levels in indigenous African infants. Pediatrics. 2004 Jun;113(6):1636-1641.
36. Chimhini GLT, Chimhuya S, Chikwasha V. Evaluation of transcutaneous bilirubinometer (DRAEGER JM 103) use in Zimbabwean newborn babies. Matern Health Neonatol Perinatal. 2018 Jan 18;4:1.
37. Moyer VA, Ahn C, Sneed S. Accuracy of clinical judgment in neonatal jaundice. Arch Pediatr Adolesc Med. 2000 Apr;154(4):391-394.